Paratek Pharmaceuticals, Inc.
PRTKNASDAQHealthcare
$2.23
+$0.04(+1.83%)
Market Cap$127828952
P/E Ratio—
52W High$3.65
52W Low$1.29
Paratek Pharmaceuticals, Inc. (PRTK) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRTK · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.15B | $0.12B | $0.04B | $0.02B | $0.02B |
| Cost of Revenue | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.13B | $0.10B | $0.03B | $0.01B | $0.02B |
| Gross Margin %(computed) | 84.71% | 82.20% | 80.12% | 78.94% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.04B | $0.03B | $0.02B | $0.04B | $0.06B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.06B |
| Total Operating Expenses | $0.17B | $0.14B | $0.11B | $0.13B | $0.12B |
| Operating Income | ($0.05B) | ($0.04B) | ($0.08B) | ($0.12B) | ($0.10B) |
| Operating Margin %(computed) | -30.65% | -34.01% | -173.50% | -698.92% | -608.08% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.02B | $0.02B | $0.01B |
| Income Before Tax | ($0.06B) | ($0.06B) | ($0.10B) | ($0.13B) | ($0.11B) |
| Income Tax Expense | $0.00B | $0.00B | $0.02B | $0.00B | $0.00B |
| Net Income | ($0.06B) | ($0.06B) | ($0.12B) | ($0.13B) | ($0.11B) |
| Net Margin %(computed) | -42.16% | -48.85% | -267.16% | -778.47% | -656.40% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.17 | $-1.22 | $-2.63 | $-3.93 | $-3.57 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.04B | 0.03B | 0.03B |
| EBITDA | ($0.04B) | ($0.04B) | ($0.07B) | ($0.11B) | ($0.10B) |
| EBITDA Margin %(computed) | -29.78% | -33.64% | -169.89% | -656.09% | -589.08% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Paratek Pharmaceuticals, Inc. data
About Paratek Pharmaceuticals, Inc. (PRTK) Income Statement
Paratek Pharmaceuticals, Inc. (PRTK) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, PRTK reported revenue of $0.15B, gross profit of $0.13B (gross margin 84.71%), and net income of ($0.06B) — a net profit margin of -42.16%.
Frequently asked questions
PRTK · 4 questionsParatek Pharmaceuticals, Inc. (PRTK) reported revenue of $0.15B for 2022, up 24.7% year-over-year.
PRTK revenuePRTK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09